MRD MONITORING BY EUROCLONALITY IGH BASED NGS APPROACH PROVIDES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA PATIENTS LACKING A CONVENTIONAL BCL2∥IGH MARKER| BIOLOGICAL RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL

被引：0

作者：

Genuardi, E. ^{[1
]}

Alessandria, B. ^{[1
]}

Della Starza, I. ^{[2
,3
]}

Guerrini, F. ^{[4
]}

Bomben, R. ^{[5
]}

Drandi, D. ^{[1
]}

Ferrante, M. ^{[1
]}

Bono, C. ^{[4
]}

Soscia, R. ^{[2
]}

Bittolo, T. ^{[5
]}

Ragaini, S. ^{[1
,6
]}

Mancuso, S. ^{[7
]}

Cencini, E. ^{[8
,9
]}

Di Renzo, N. ^{[10
]}

Mannarella, C. ^{[11
]}

Murineddu, M. ^{[12
]}

Stefoni, V. ^{[13
]}

Centurioni, R. ^{[14
]}

Baldini, L. ^{[15
]}

Civita, A. M. ^{[1
]}

Gattei, V. ^{[5
]}

Galimberti, S. ^{[4
]}

Del Giudice, I. ^{[2
]}

Bruno, B. ^{[1
,6
]}

Federico, M. ^{[16
]}

Ladetto, M. ^{[17
]}

Pott, C. ^{[17
,18
]}

Luminari, S. ^{[19
,20
]}

Ferrero, S. ^{[1
,6
]}

机构：

[1] Univ Torino, Div Ematol, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy

[2] Univ Roma La Sapienza, Dipartimento Med Traslaz & Precis, Ematol, Rome, Italy

[3] AIL Roma ODV, Rome, Italy

[4] Univ Pisa, Ematol, Dipartimento Med Clin & Sperimentale, Pisa, Italy

[5] CRO, Unita Oncoematol, Verona, Italy

[6] AOU Citta Salute & Sci, Div Ematol & Trapianto Cellule Staminali, Turin, Italy

[7] Univ Palermo, Policlin Paolo Giaccone, Unita Ematol, Dipartimento Promoz Salute Maternoinfantile ProMI, Palermo, Italy

[8] Azienda Osped Univ Senese, Ematol, Siena, Italy

[9] Univ Siena, Siena, Italy

[10] Osped Vito Fazzi, Dipartimento Ematol, Lecce, Italy

[11] Osped Madonna Grazie, Unita Ematol, Matera, Italy

[12] Osped San Francesco, Unita Ematol & Trapianto Midollo Osseo, Nuoro, Italy

[13] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[14] UOC Med Interna Civitanova Marche, Civitanova Marche, Italy

[15] Univ Milan, Dipartimento Oncol & Emato Oncol, Milan, Italy

[16] Univ Modena & ggio Emilia, Dipartimento CHIMOMO, Reggio Emilia, Italy

[17] Univ Piemonte Orientale, Dipartimento Med Traslaz, SCDU Ematol, AO SS Antonio & Biagio & Cesare Arrigo, Vercelli, Italy

[18] Univ Hosp Schleswig Holstein, Med Dept 2, Campus Kiel, Kiel, Germany

[19] Univ Modena & Reggio Emilia, Dipartimento Clin & Salute Pubbl Arcispedale S Ma, Reggio Emilia, Italy

[20] Dipartimento Med Diagnost, Div Ematol, Rome, Italy

来源：

HAEMATOLOGICA | 2024年 / 109卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

C43

引用

页码：36 / 37

页数：2

共 5 条

[1] MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
Genuardi, Elisa
Alessandria, Beatrice
Della Starza, Irene
Guerrini, Francesca
Bomben, Riccardo
Drandi, Daniela
Ferrante, Martina
Bono, Clara
Soscia, Roberta
Bittolo, Tamara
Ragaini, Simone
Mancuso, Salvatrice
Cencini, Emanuele
Di Renzo, Nicola
Mannarella, Clara
Murineddu, Marco
Stefoni, Vittorio
Centurioni, Riccardo
Baldini, Luca
Civita, Aurora Maria
BLOOD, 2023, 142
[2] A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
Ladetto, Marco
Ferrero, Simone
Del Giudice, Ilaria
Galimberti, Sara
Gattei, Valter
Marcheselli, Luigi
Mantoan, Barbara
Genuardi, Elisa
Alessandria, Beatrice
Ferrante, Martina
Dogliotti, Irene
Della Starza, Irene
De Novi, Lucia Anna
Cavalli, Marzia
Grassi, Susanna
Ciabatti, Elena
Guerrini, Francesca
Bomben, Riccardo
Degan, Massimo
Zaina, Eva
Perrone, Tommasina
Petrini, Mario
Re, Francesca
Olivieri, Attilio
Usai, Sara Veronica
Mannina, Donato
Falini, Brunangelo
Scalabrini, Delia Rota
Stefani, Pietro Maria
Ballerini, Filippo
Federico, Massimo
Luminari, Stefano
BLOOD, 2021, 138
[3] NEXT GENERATION SEQUENCING PROVIDES NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA: BIOLOGICAL RESULTS FROM FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL
Genuardi, E.
Ferrero, S.
Della Starza, I.
Grassi, S.
Bomben, R.
Mantoan, B.
Drandi, D.
Dogliotti, I.
Alessandria, B.
Ferrante, M.
Ragaini, S.
Civita, A. M.
Ghiggi, C.
Pulsoni, A.
Ronconi, S.
Merli, M.
Califano, C.
Castellino, C.
Bari, A.
Conconi, A.
De Novi, L. A.
Del Giudice, I.
Gattei, V.
Galimberti, S.
Luminari, S.
Ladetto, M.
Federico, M.
HAEMATOLOGICA, 2021, 106 (10) : 25 - 25
[4] Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL)
Galimberti, Sara
Luminari, Stefano
Ciabatti, Elena
Testi, Rossana
Dondi, Alessandra
Ladetto, Marco
Piccaluga, Pier Paolo, Sr.
Del Giudice, Ilaria
Gazzola, Anna
Monitillo, Luigia
Mantoan, Barbara
della Starza, Irene
Cavalli, Marzia
Arcaini, Luca
Tucci, Alessandra
Di Raimondo, Francesco
Rigacci, Luigi
Pulsoni, Alessandro
Vitolo, Umberto
Vallisa, Daniele
Bertoldero, Giovanni
Gaidano, Gianluca
Petrini, Mario
Federico, Massimo
BLOOD, 2012, 120 (21)
[5] PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)
Ladetto, Marco
Lobetti-Bodoni, Chiara
Mantoan, Barbara
Evangelista, Andrea
Boccomini, Carola
Genuardi, Elisa
Botto, Barbara
Baldini, Luca
Rossi, Giuseppe
Pulsoni, Alessandro
Di Raimondo, Francesco
Rigacci, Luigi
Pinto, Antonello
Petrini, Mario
Sacchi, Stefano
Rota-Scalabrini, Delia
Gugliotta, Luigi
Fanin, Renato
Gallamini, Andrea
Parvis, Guido
Specchia, Giorgina
Musto, Pellegrino
Olivero, Barbara
Gamba, Enrica
Ciccone, Giovannino
Vitolo, Umberto
BLOOD, 2012, 120 (21)

← 1 →